Effects of cilostazol on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a multicenter prospective, randomized, open-label blinded end point trial.

Abstract

OBJECT:

Cerebral vasospasm following aneurysmal subarachnoid hemorrhage (SAH) is a major cause of subsequent morbidity and mortality. Cilostazol, a selective inhibitor of phosphodiesterase 3, may attenuate cerebral vasospasm because of its antiplatelet and vasodilatory effects. A multicenter prospective randomized trial was conducted to investigate the effect of cilostazol on cerebral vasospasm.

METHODS:

Patients admitted with SAH caused by a ruptured anterior circulation aneurysm who were in Hunt and Kosnik Grades I to IV and were treated by clipping within 72 hours of SAH onset were enrolled at 7 neurosurgical sites in Japan. These patients were assigned to one of 2 groups: the usual therapy group (control group) or the add-on 100 mg cilostazol twice daily group (cilostazol group). The group assignments were done by a computer-generated randomization sequence. The primary study end point was the onset of symptomatic vasospasm. Secondary end points were the onset of angiographic vasospasm and new cerebral infarctions related to cerebral vasospasm, clinical outcome as assessed by the modified Rankin scale, and length of hospitalization. All end points were assessed for the intention-to-treat population.

RESULTS:

Between November 2009 and December 2010, 114 patients with SAH were treated by clipping within 72 hours from the onset of SAH and were screened. Five patients were excluded because no consent was given. Thus, 109 patients were randomly assigned to the cilostazol group (n = 54) or the control group (n = 55). Symptomatic vasospasm occurred in 13% (n = 7) of the cilostazol group and in 40% (n = 22) of the control group (p = 0.0021, Fisher exact test). The incidence of angiographic vasospasm was significantly lower in the cilostazol group than in the control group (50% vs 77%; p = 0.0055, Fisher exact test). Multiple logistic analyses demonstrated that nonuse of cilostazol is an independent factor for symptomatic and angiographic vasospasm. The incidence of new cerebral infarctions was also significantly lower in the cilostazol group than in the control group (11% vs 29%; p = 0.0304, Fisher exact test). Clinical outcomes at 1, 3, and 6 months after SAH in the cilostazol group were better than those in the control group, although a significant difference was not shown. There was also no significant difference in the length of hospitalization between the groups. No severe adverse event occurred during the study period.

CONCLUSIONS:

Oral administration of cilostazol is effective in preventing cerebral vasospasm with a low risk of severe adverse events. Clinical trial registration no. UMIN000004347, University Hospital Medical Information Network Clinical Trials Registry.

• Authors: Nobuo Senbokuya, Hiroyuki Kinouchi, Kazuya Kanemaru, Yasuhiro Ohashi, Akira Fukamachi, Shinichi Yagi, Tsuneo Shimizu, Koro Furuya, Mikito Uchida, Nobuyasu Takeuchi, Shin Nakano, Hidehito Koizumi, Chikashi Kobayashi, Isao Fukasawa, Teruo Takahashi, Katsuhiro Kuroda, Yoshihisa Nishiyama, Hideyuki Yoshioka, Toru Horikoshi
• Journal: Journal of neurosurgery (J Neurosurg) Vol. 118 Issue 1 Pg. 121-30 (Jan 2013) ISSN: 1933-0693 [Electronic] United States
• PMID: 23039152 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Phosphodiesterase 3 Inhibitors
• Tetrazoles
• Vasodilator Agents
• Cilostazol

Topics

• Aged
• Cilostazol
• Female
• Humans
• Male
• Middle Aged
• Phosphodiesterase 3 Inhibitors (therapeutic use)
• Prospective Studies
• Subarachnoid Hemorrhage (complications)
• Tetrazoles (therapeutic use)
• Treatment Outcome
• Vasodilator Agents (therapeutic use)
• Vasospasm, Intracranial (drug therapy, etiology, prevention & control)